RT Journal Article
SR Electronic
T1 The emergence of SARS-CoV-2 lineages and associated antibody responses among asymptomatic individuals in a large university community
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.30.23285195
DO 10.1101/2023.01.30.23285195
A1 Merling, Marlena R.
A1 Williams, Amanda
A1 Mahfooz, Najmus
A1 Ruane-Foster, Marisa
A1 Smith, Jacob
A1 Jahnes, Jeff
A1 Ayers, Leona W.
A1 Bazan, Jose A.
A1 Norris, Alison
A1 Norris Turner, Abigail
A1 Oglesbee, Michael
A1 Faith, Seth A.
A1 Quam, Mikkel B.
A1 Robinson, Richard T.
YR 2023
UL http://medrxiv.org/content/early/2023/02/01/2023.01.30.23285195.abstract
AB SARS-CoV-2 (CoV2) infected, asymptomatic individuals are an important contributor to COVID transmission. CoV2-specific immunoglobulin (Ig)—as generated by the immune system following infection or vaccination—has helped limit CoV2 transmission from asymptomatic individuals to susceptible populations (e.g. elderly). Here, we describe the relationships between COVID incidence and CoV2 lineage, viral load, saliva Ig levels (CoV2-specific IgM, IgA and IgG) and inhibitory capacity in asymptomatic individuals between Jan 2021 and May 2022. These data were generated as part of a large university COVID monitoring program and demonstrate that COVID incidence among asymptomatic individuals occurred in waves which mirrored those in surrounding regions, with saliva CoV2 viral loads becoming progressively higher in our community until vaccine mandates were established. Among the unvaccinated, infection with each CoV2 lineage (pre-Omicron) resulted in saliva Spike-specific IgM, IgA and IgG responses, the latter increasing significantly post-infection and being more pronounced than N-specific IgG responses. Vaccination resulted in significantly higher Spike-specific IgG levels compared to unvaccinated infected individuals, and uninfected vaccinees’ saliva was more capable of inhibiting Spike function. Vaccinees with breakthrough Delta infections had Spike-specific IgG levels comparable to those of uninfected vaccinees; however, their ability to inhibit Spike binding was diminished. These data demonstrate that COVID vaccines achieved hoped-for effects in our community, including the generation of mucosal antibodies that inhibit Spike and lower community viral loads, and suggest breakthrough Delta infections were not due to an absence of vaccine-elicited Ig, but instead limited Spike binding activity in the face of high community viral loads.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by The Ohio State UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was reviewed and approved by The Ohio State University Biomedical Sciences Institutional Review Board (ID #2021H0080).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptPCRPOSan individual or saliva specimen that was PCR positive for CoV2 (CT value ≤ 40) ;PCRNEGan individual or saliva specimen that was PCR negative for CoV2;Spike and Nunless otherwise stated the Spike and N proteins of CoV2 (not any other coronavirus);CoV2-Igimmunoglobulin of any isotype that recognizes any CoV2 antigen;IgMSpikeIgM that recognizes Spike;IgASpikeIgA that recognizes Spike;IgGSpikeIgG that recognizes Spike;IgGRBDIgG that recognizes the Spike Receptor Binding Domain;IgGNIgG that recognizes the N protein;VaxPOSan individual who was fully vaccinated against COVID (but not boosted) prior to saliva specimen collection;VaxNEGan individual who was not fully vaccinated against COVID prior to saliva specimen collection;NewPOSan individual who at the time of saliva collection was PCRPOS for the first time;PriorPOSan individual who at the time of saliva collection was PCRNEG but who had a prior CoV2 infection (i.e. the individual had been PCRPOS 3-9 months prior).